Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 7—July 2022
Research

Targeted Screening for Chronic Q Fever, the Netherlands

Daphne F.M. ReukersComments to Author , Pieter T. de Boer, Alfons O. Loohuis, Peter C. Wever, Chantal P. Bleeker-Rovers, Arianne B. van Gageldonk-Lafeber, Wim van der Hoek, and Aura Timen
Author affiliations: National Institute for Public Health and the Environment, Bilthoven, the Netherlands (D.F.M. Reukers, P.T. de Boer, A.B. van Gageldonk-Lafeber, W. van der Hoek, A. Timen); Q-Support Foundation, ’s-Hertogenbosch, the Netherlands (A.O. Loohuis); Radboud University Medical Center, Nijmegen, the Netherlands (A.O. Loohuis, C.P. Bleeker-Rovers); Jeroen Bosch Hospital, ’s-Hertogenbosch (P.C. Wever); Vrije Universiteit, Amsterdam (A. Timen)

Main Article

Figure 2

Relationship between the prevalence of chronic Q fever and incremental cost-effectiveness ratio of a screening program to detect chronic Q fever, the Netherlands, and screening costs for the program compared with a previously published analysis (7). Symbols on the line are based on a high-prevalence and low prevalence rate scenario as used in the previously published analysis and are based on actual prevalence rates found in this study. CVRF, cardiovascular risk factor; IC, immunocompromised; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.

Figure 2. Relationship between the prevalence of chronic Q fever and incremental cost-effectiveness ratio of a screening program to detect chronic Q fever, the Netherlands, and screening costs for the program compared with a previously published analysis (7). Symbols on the line are based on a high-prevalence and low prevalence rate scenario as used in the previously published analysis and are based on actual prevalence rates found in this study. CVRF, cardiovascular risk factor; IC, immunocompromised; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.

Main Article

References
  1. Maurin  M, Raoult  D. Q fever. Clin Microbiol Rev. 1999;12:518–53. DOIPubMedGoogle Scholar
  2. van Roeden  SE, Wever  PC, Kampschreur  LM, Gruteke  P, van der Hoek  W, Hoepelman  AIM, et al. Chronic Q fever-related complications and mortality: data from a nationwide cohort. Clin Microbiol Infect. 2019;25:1390–8. DOIPubMedGoogle Scholar
  3. van der Hoek  W, Hogema  BM, Dijkstra  F, Rietveld  A, Wijkmans  CJ, Schneeberger  PM, et al. Relation between Q fever notifications and Coxiella burnetii infections during the 2009 outbreak in The Netherlands. Euro Surveill. 2012;17:20058. DOIPubMedGoogle Scholar
  4. Wever  PC, Arts  CH, Groot  CA, Lestrade  PJ, Koning  OH, Renders  NH. [Screening for chronic Q fever in symptomatic patients with an aortic aneurysm or prosthesis] [in Dutch]. Ned Tijdschr Geneeskd. 2010;154:A2122.PubMedGoogle Scholar
  5. Kampschreur  LM, Oosterheert  JJ, Hoepelman  AI, Lestrade  PJ, Renders  NH, Elsman  P, et al. Prevalence of chronic Q fever in patients with a history of cardiac valve surgery in an area where Coxiella burnetii is epidemic. Clin Vaccine Immunol. 2012;19:1165–9. DOIPubMedGoogle Scholar
  6. Hagenaars  JC, Wever  PC, van Petersen  AS, Lestrade  PJ, de Jager-Leclercq  MG, Hermans  MH, et al. Estimated prevalence of chronic Q fever among Coxiella burnetii seropositive patients with an abdominal aortic/iliac aneurysm or aorto-iliac reconstruction after a large Dutch Q fever outbreak. J Infect. 2014;69:154–60. DOIPubMedGoogle Scholar
  7. de Lange  MMA, Scheepmaker  A, van der Hoek  W, Leclercq  M, Schneeberger  PM. Risk of chronic Q fever in patients with cardiac valvulopathy, seven years after a large epidemic in the Netherlands. PLoS One. 2019;14:e0221247. DOIPubMedGoogle Scholar
  8. de Boer  PT, de Lange  MMA, Wielders  CCH, Dijkstra  F, van Roeden  SE, Bleeker-Rovers  CP, et al. Cost-effectiveness of screening program for chronic Q fever, the Netherlands. Emerg Infect Dis. 2020;26:238–46. DOIPubMedGoogle Scholar
  9. Wegdam-Blans  MC, Kampschreur  LM, Delsing  CE, Bleeker-Rovers  CP, Sprong  T, van Kasteren  ME, et al.; Dutch Q fever Consensus Group. Chronic Q fever: review of the literature and a proposal of new diagnostic criteria. J Infect. 2012;64:247–59. DOIPubMedGoogle Scholar
  10. Melenotte  C, Gay  L, Mezouar  S, Bardin  N, Raoult  D, Mège  JL. The sexual dimorphism of anticardiolipin autoantibodies in acute Q fever patients. Clin Microbiol Infect. 2019;25:763.e1–3. DOIPubMedGoogle Scholar
  11. Melenotte  C, Protopopescu  C, Million  M, Edouard  S, Carrieri  MP, Eldin  C, et al. Clinical features and complications of Coxiella burnetii infections from the French National Reference Center for Q fever. JAMA Netw Open. 2018;1:e181580. DOIPubMedGoogle Scholar
  12. Pijnacker  R, Reimerink  J, Smit  LAM, van Gageldonk-Lafeber  AB, Zock  J-P, Borlée  F, et al. Remarkable spatial variation in the seroprevalence of Coxiella burnetii after a large Q fever epidemic. BMC Infect Dis. 2017;17:725. DOIPubMedGoogle Scholar
  13. Buijs  SB, van Roeden  SE, van Werkhoven  CH, Hoepelman  AIM, Wever  PC, Bleeker-Rovers  CP, et al. The prognostic value of serological titres for clinical outcomes during treatment and follow-up of patients with chronic Q fever. Clin Microbiol Infect. 2021;27:1273–8. DOIPubMedGoogle Scholar
  14. Buijs  SB, Bleeker-Rovers  CP, van Roeden  SE, Kampschreur  LM, Hoepelman  AIM, Wever  PC, et al. Still new chronic Q fever cases diagnosed eight years after a large Q fever outbreak. Clin Infect Dis. 2021;73:1476–83. DOIPubMedGoogle Scholar
  15. National Institute for Public Health and the Environment. Advisory letter for detection of chronic Q fever patients, 2021 [in Dutch] [cited 2021 Oct 1]. https://www.rijksoverheid.nl/documenten/publicaties/2021/09/15/adviesbrief-opsporing-chronische-q-koortspatienten

Main Article

Page created: May 06, 2022
Page updated: June 18, 2022
Page reviewed: June 18, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external